Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06840392 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
A Phase 3 study of Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 555
- Enrollment target
- 20
- Study locations
NCT06840392 is a Phase 3 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 555 participants, roughly in line with the 587-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target. The trial reports 20 study locations across 10 states.
The verdict
NCT06840392, a Phase 3 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 555 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Conditions Studied
Interventions
- DRUG Remibrutinib Dose A
- DRUG Remibrutinib Dose B
- DRUG Placebo 1
- DRUG Placebo 2
Study Locations (20)
Florida
- Driven Research - Coral Gables
- Floridian Research Institute - Miami
- Sarasota Arthritis Res Ctr - Sarasota
- University Of South Florida - Tampa
California
- Ctr for Dermatology Clinical Res - Fremont
- USC Keck School of Medicine - Los Angeles
- MedDerm Associates - San Diego
Illinois
- Northwestern University - Chicago
- Endeavor Health - Glenview
- Dundee Dermatology - West Dundee
Arizona
- CTT Research - Gilbert
- Ctr Dermatology and Plastic Surgery - Scottsdale
Georgia
- Emory School of Med Dermatology - Atlanta
- Atlanta Biomedical Clin Res LLC - Atlanta
Massachusetts
- Beth Israel Deaconess Med Center - Boston
- Metro Boston Clinical Partners - Brighton
Alabama
- Total Skin and Beauty Dermatology Center PC - Birmingham
Indiana
- Southern IN Clinical Trials - New Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2028-02-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06840392
The ClinicalTrials.gov registry entry for NCT06840392 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 555 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 587-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 4 interventions - of which Remibrutinib Dose A is the first listed.
NCT06840392 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06840392 about?
NCT06840392 is a clinical study titled "A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa". The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
What is the current status of trial NCT06840392?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 555 participants. The study started on 2025-03-20. Estimated completion is 2028-02-07.
What conditions does trial NCT06840392 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06840392?
The interventions under investigation include: Remibrutinib Dose A (DRUG), Remibrutinib Dose B (DRUG), Placebo 1 (DRUG), Placebo 2 (DRUG).
Who is sponsoring clinical trial NCT06840392?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06840392 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.